Reference Detail

Ref Type
PMID
Authors Funda Meric-Bernstam, Mansoor N. Saleh, Jeffrey R. Infante, Sanjay Goel, Gerald Steven Falchook, Geoffrey Shapiro, Ki Y Chung, Robert Martin Conry, David S. Hong, Judy Sing-Zan Wang, Ulrich Steidl, Loren D. Walensky, Vincent Guerlavais, et al.
Title Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas
Journal Journal of Clinical Oncology
Vol
Issue
Date
URL http://abstracts.asco.org/199/AbstView_199_187803.html
Abstract Text J Clin Oncol 35, 2017 (suppl; abstr 2505)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
TP53 wild-type Advanced Solid Tumor predicted - sensitive ALRN-6924 Phase I Actionable In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 45% (25/55), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 21 patients demonstrating stable disease (J Clin Oncol 35, 2017 (suppl; abstr 2505)). detail...
TP53 wild-type colorectal cancer sensitive ALRN-6924 Phase I Actionable In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with colorectal cancer (J Clin Oncol 35, 2017 (suppl; abstr 2505)). detail...
TP53 wild-type Merkel cell carcinoma sensitive ALRN-6924 Phase I Actionable In a Phase I trial, ALRN-6924 treatment in a patient with Merkel cell carcinoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)). detail...
TP53 wild-type liposarcoma sensitive ALRN-6924 Phase I Actionable In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with liposarcoma (J Clin Oncol 35, 2017 (suppl; abstr 2505)). detail...
TP53 wild-type peripheral T-cell lymphoma sensitive ALRN-6924 Phase I Actionable In a Phase I trial, ALRN-6924 treatment in a patient with peripheral T-cell lymphoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)). detail...
TP53 wild-type lymphoma predicted - sensitive ALRN-6924 Phase I Actionable In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 45% (25/55), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 21 patients demonstrating stable disease (J Clin Oncol 35, 2017 (suppl; abstr 2505)). detail...